UNCY UNICYCIVE THERAPEUTICS INC

Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

LOS ALTOS, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14, 2025 at 11 a.m. ET.

A link to the webcast may be accessed on the Unicycive website under the Investors section: .

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit  and follow us on  and .

Investor Contact:

Kevin Gardner

LifeSci Advisors

Media Contact:

Rachel Visi

Real Chemistry

SOURCE: Unicycive Therapeutics, Inc.



EN
07/07/2025

Underlying

UNCYUNICYCIVE THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on UNICYCIVE THERAPEUTICS INC

 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Ki...

Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference LOS ALTOS, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14, 2025 at 11 a.m. ET. A link to the webcast may be accessed on the Unicycive website under the I...

16h / 52m 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics Announces Receipt of Complete Response Letter f...

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis --Complete Response Letter (CRL) cited deficiencies previously identified at a third-party manufacturing vendor unrelated to Oxylanthanum Carbonate (OLC) --No other concerns stated, including pre-clinical, clinical, or safety data --The Company identified a second manufacturing vendor that has already produced OLC drug product, which could also be used to support the resolution of the Clinical Ma...

June 30, 2025 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

Unicycive Therapeutics, Inc. Announces Reverse Stock Split Shares Expected to Begin Trading on Split-Adjusted Basis on June 20, 2025 LOS ALTOS, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that it will implement a 1-for-10 reverse split of the issued shares of its common stock, effective at 4:01 p.m. Eastern Time on June 18, 2025. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on J...

June 17, 2025 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Provides Update on New Drug Application for Oxylanthanum Car...

Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - The U.S. Food and Drug Administration (FDA) identified deficiencies at a third-party manufacturing vendor - FDA to provide final decision by PDUFA action date of June 28, 2025 LOS ALTOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY or the “Company”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced an update on its New Drug ...

June 10, 2025 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics to Present at Upcoming Investor Conferences

Unicycive Therapeutics to Present at Upcoming Investor Conferences LOS ALTOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at two upcoming virtual investment conferences. Event:   Lytham Partners Spring 2025 Investor Conference Type:   Fireside ChatDate/Time:   Thursday, May 29, 2025, at 12:30 p.m. ET Event:   Noble Capital Markets 2025 Emerging Growth Virtual Equity Confe...

May 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch